Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

NACompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

October 31, 2004

Conditions
HypertensionType 2 Diabetes
Interventions
DRUG

eprosartan/HCTZ

Trial Locations (63)

Unknown

Site 26, Calgary

Site 27, Montreal

Site 30, Québec

Site 31, Thornhill

Site 28, Vancouver

Site 29, Winnipeg

Site 39, Holbæk

Site 38, Roskilde

Site 40, Viborg

Site 4, Anzin

Site 3, Blois

Site 10, Chemellier

Site 11, Cholet

Site 15, Cholet

Site 16, Cholet

Site 14, La Jubaudière

Site 13, Le Mesnil-en-Vallée

Site 7, Mûrs-Erigné

Site 12, Saint Pierre Montlim

Site 9, Saumur

Site 8, Segré

Site 6, Thouars

Site 2, Tours

Site 5, Vieux-Condé

Site 20, Bad Muenster

Site 22, Flörsheim

Site 19, Kirweiler

Site 21, Lambrecht

Site 25, Lindau

Site 24, Lutherstadt

Site 18, Lüneburg

Site 17, Riesa

Site 23, Waldbrunn

Site 62, Bologna

Site 60, Napoli

Site 58, Padua

Site 59, Palermo

Site 63, Pavia

Site 61, Pisa

Site 64, Torino

Site 43, Ålesund

Site 42, Bergen

Site 44, Horten

Site 41, Skedsmokorset

Site 55, Badajoz

Site 51, Badalona

Site 56, Barcelona

Site 57, Barcelona

Site 54, Ciudad Real

Site 53, Granada

Site 52, Madrid

Site 48, Ängelholm

Site 47, Gothenburg

Site 46, Helsingborg

Site 45, Kristianstat

Site 50, Malmo

Site 49, Stockholm

Site 33, Aberdeen

Site 36, Bath

Site 37, Liverpool

Site 34, Manchester

Site 32, Oldham

Site 35, Rugby

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00160160 - Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes | Biotech Hunter | Biotech Hunter